The constant use of vague terms like “ongoing,” “coming weeks,”...

The constant use of vague terms like “ongoing,” “coming weeks,” and “coming months” has become meaningless. Shareholders are no longer interested in hollow updates—they want tangible outcomes, not the same recycled language that’s been used for over 20 years. These words might as well be deleted from their vocabulary.

The recent focus on an animal model—particularly after 24+ years in so-called business—is raising more questions than confidence. Why only now? Why wasn’t this explored years ago? It appears more like a strategic delay to justify prolonging salaries and operations rather than a genuine breakthrough.

This pattern is all too familiar: introduce an animal model, spend years on data analysis, move to human trials, follow with more years of data collection, and eventually promise headline results that never come. All the while, the biotech space becomes increasingly crowded, and competitors move ahead. Investors have every right to be skeptical. Without real progress, trust is eroding quickly.

"In parallel with completing the above HBV animal study, the Company is continuing its
commercialisation activities in collaboration with the US-based C14 Consulting Group. The
recent Biotechnology Industry Organisation annual meeting (BIO2025) in Boston, MA,
USA provided an opportunity for face-to-face meetings with potential partners. Discussions
and sharing of detailed information on Biotron programs, with a focus on HIV-1, are
ongoing "